SLC1A5 and colorectal carcinoma: Thus, our data unveil the upregulation of the selected AATs (SLC1A5/ASCT2, SLC7A5/LAT1, and SLC38A2/SNAT2) as a prognostic marker of poor survival of patients with CRC, useful for cancer patient stratification, in particular with regard to the KRAS mutant subtype of patients.